Translating SYNCHRONIZE-1 to Practice: Who May Benefit From Dual GLP-1/Glucagon Receptor Agonism?

This episode, titled 'Translating SYNCHRONIZE-1 to Practice: Who May Benefit From Dual GLP-1/Glucagon Receptor Agonism?' features Mazen Noureddin, MD, MHSc, FAASLD discussing the following critical questions:

Please describe how weight loss and liver fat reductions in this regard may translate to improved outcomes for your patients, pending FDA approval of survodutide.

From a patient profile standpoint, who do you think stands to benefit most from a dual GLP-1/glucagon receptor agonist approach?

Noureddin drew on the prior Phase 2 survodutide data published in the New England Journal of Medicine, which demonstrated improvements in steatohepatitis histology and significant fibrosis reduction to contextualize the SYNCHRONIZE-1 findings, noting that MRI-based proton density fat fraction reduction has been shown to correlate with histologic improvement in steatohepatitis and fibrosis, suggesting the magnitude of liver fat reduction observed in SYNCHRONIZE-1 is a predictive surrogate for the histologic endpoints being evaluated in the ongoing Phase 3 LEVERAGE and LEVERAGE Cirrhosis trials. Noureddin identified patients with obesity and concurrent liver disease as the population most likely to derive the greatest benefit from a dual GLP-1/glucagon receptor agonist approach, emphasizing that survodutide's holistic profile of significant weight loss, visceral fat reduction, lean mass preservation, and hepatic fat normalization makes it a particularly compelling choice for patients whose metabolic burden extends beyond the liver and who stand to benefit from a single therapy that addresses multiple disease drivers simultaneously.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'The Endocrinologist's View: Obesity, MASH, and the Metabolic Dysfunction That Connects Them,' Jaime Almandoz, MD will share his perspective as an endocrinologist on how obesity, MASH, type 2 diabetes, and cardiovascular disease should be understood as different manifestations of the same underlying metabolic dysfunction.